Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept;Psoríase eritrodérmica refratária em criança com excelente resposta ao etanercepte

Anais Brasileiros de Dermatologia

Volumn 86, Issue 4 SUPPL. 1, 2011, Pages 144-147

  Fraga, Naiara Abreu de Azevedo ^a   Paim, Maria de Fátima ^a   Follador, Ivonise ^a   Ramos, Andréia Nogueira ^a   Rêgo, Vitória Regina Pedreira de Almeida ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Child; Psoriasis; Therapy

Indexed keywords

CYCLOSPORIN; ETANERCEPT; METHOTREXATE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CASE REPORT; CHILD; DISEASE SEVERITY; DRUG INDICATION; DRUG WITHDRAWAL; ERYTHRODERMA; ERYTHRODERMIC PSORIASIS; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PSORIASIS; PSORIASIS VULGARIS; STOMACH DISEASE; TREATMENT OUTCOME;

EID: 81055144974     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/s0365-05962011000700038     Document Type: Article

References (15)

1. Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62:979-87.
2. Sukhatme SV, Gottlieb AB. Pediatrics psoriasis: updates in biologic therapies. Dermatologic Therapy. 2009;22:34-9.
3. Romiti R, Maragno L, Arnone M, Takahashi MDF. Psoríase na infância e na adolescência. An Bras Dermatol. 2009;84:9-22.
4. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162:633-6.
5. Silverberg NB. Pediatric Psroriasis: un uptade. Ther Clin Risk Manag. 2009;5:849-56.
6. Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241-51.
7. Boehncke WH, Brasie RA, Barker J, Chimenti S, Daudén E, de Rie M, et al. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol. 2006;20:988-98.
8. Azulay-Abulafia L, Felix P. Imunobiológicos na Psoríase. In: Sociedade Brasileira de Dermatologia, organizador. Consenso Brasileiro de psoríase. Rio de Janeiro: Sociedade Brasileira de Dermatologia; 2009. p.85-96
9. Marji JS, Marcus R, Moennich J, Mackay-Wiggan J. Use of biologic agents in pediatric psoriasis. J Drugs Dermatol. 2010;9:975-86.
10. Benoit S, Hamm H. Childhood psoriasis. Clin Dermatol. 2007;25:555-62
11. Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr,et al. Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62:655-62.
12. Sánchez Carazo JL, Mahiques Santos L, Oliver Martinez V. Safety of Etanercept in psoriasis: a critical review. Drug Safety. 2006;29:675-85.
13. Hawrot AC, Metry DW, Theos AJ, Levy ML. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol 2006;23:67-71.
14. Papoutsaki M, Costanzo A, Mazzotta A, Gramiccia T, Soda R, Chimenti S. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol. 2006;154: 181-3.
15. Safa G., Loppin M., Bousser A., Barbarot S. Etanercept in 7-year-old boy with severe and recalcitrant psoriasis. J Am Acad Dermatol. 2007;56:S19-20.